Intravenous Immunoglobulin Use in Hemolytic Disease Due to ABO Incompatibility to Prevent Exchange Transfusion

Basit Öğe Kaydı
dc.authorscopusid57217123588
dc.authorscopusid9042890600
dc.authorscopusid6603868038
dc.authorscopusid8158471600
dc.authorscopusid6506656202
dc.authorscopusid6506224256
dc.authorscopusid23994946300
dc.contributor.authorOkulu E.
dc.contributor.authorErdeve O.
dc.contributor.authorKilic I.
dc.contributor.authorOlukman O.
dc.contributor.authorCalkavur S.
dc.contributor.authorBuyukkale G.
dc.contributor.authorCetinkaya M.
dc.date.accessioned2024-08-04T20:03:38Z
dc.date.available2024-08-04T20:03:38Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: Intravenous immunoglobulin (IVIG) has been widely used to treat the hemolytic disease of the newborn (HDN). Although it has been shown that IVIG treatment reduces the duration of phototherapy and hospitalization, the use of IVIG in hemolytic disease due to ABO incompatibility has been controversial in recent years. This study aimed to investigate the role of IVIG in the prevention of exchange transfusion in infants with ABO HDN who presented with bilirubin levels at or above the level of exchange transfusion. Materials and Methods: This study evaluated the data of infants with ABO HDN in the Turkish Neonatal Jaundice Online Registry. The infants with ABO HDN who met the total serum bilirubin level inclusion criteria (within 2–3 mg/dL of exchange transfusion or even above exchange transfusion level) were included in the study according to the guidelines from the American Academy of Pediatrics and the Turkish Neonatal Society. All patients were managed according to the unit protocols recommended by these guidelines and received light-emitting diode (LED) phototherapy. Infants who only received LED phototherapy, and who received one dose of IVIG with LED phototherapy were compared. Results: During the study period, 531 term infants were included in the study according to inclusion criteria. There were 408 cases in the phototherapy-only group, and 123 cases in the IVIG group. The demographic findings and the mean bilirubin and reticulocyte levels at admission were similar between the groups (p > 0.05), whereas the mean hemoglobin level was slightly lower in the IVIG group (p = 0.037). The mean age at admission was earlier, the need for exchange transfusion was higher, and the duration of phototherapy was longer in the IVIG group (p < 0.001, p = 0.001, and p < 0.001, respectively). The rate of re-hospitalization and acute bilirubin encephalopathy (ABE) was higher in the IVIG group (p < 0.001 and p = 0.01, respectively). Conclusion: In this study, we determined that one dose of IVIG did not prevent an exchange transfusion nor decrease the duration of phototherapy in infants, who had bilirubin levels near or at exchange transfusion level, with hemolytic disease due to ABO incompatibility. Copyright © 2022 Okulu, Erdeve, Kilic, Olukman, Calkavur, Buyukkale, Cetinkaya, Ulubas, Demirel, Hanta, Ertugrul, Gultekin, Tuncer, Demir, Bilgin, Narli, Yildiz, Terek, Koroglu, Seren, Ozyazici, Ozdemir, Turgut, Narter, Akin, Ozyazici, Zenciroglu, Asker, Gokmen, Salihli, Bulbul, Zubarioglu, Atasay, Koc and Turkish Neonatal Society IVIG Study Group.en_US
dc.description.sponsorshipThis study was supported by the Turkish Neonatal Society, and the financial fund was used to create the Turkish Neonatal Jaundice Online Registry database.en_US
dc.identifier.doi10.3389/fped.2022.864609
dc.identifier.issn2296-2360
dc.identifier.scopus2-s2.0-85133912076en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3389/fped.2022.864609
dc.identifier.urihttps://hdl.handle.net/11616/91981
dc.identifier.volume10en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Pediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectABO incompatibilityen_US
dc.subjectexchange transfusionen_US
dc.subjecthemolytic disease of the newbornen_US
dc.subjectintravenous immunoglobulinen_US
dc.subjectlight-emitting diodeen_US
dc.subjectphototherapyen_US
dc.titleIntravenous Immunoglobulin Use in Hemolytic Disease Due to ABO Incompatibility to Prevent Exchange Transfusionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu